NF-κB-IN-14

• UNSPSC Description:

  NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC50: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model[1].

• Target Antigen:

  NF-κB; Toll-like Receptor (TLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/nf-κb-in-14.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC=C(/C=C/CN2C=NC3=C(Cl)N=C(Cl)N=C23)C=C1

• Molecular Weight:

  319.19

• References & Citations:

  [1]Pham L, et al. Synthesis of 9-Cinnamyl-9H-purine Derivatives as Novel TLR4/MyD88/NF-κB Pathway Inhibitors for Anti-inflammatory Effects. ACS Med Chem Lett. 2023 Nov 27;14(12):1839-1847.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3019972-01-8